Children 5 through 11 years of age are now authorized to receive a booster dose at least five months after the second dose of the two-dose primary series
Viralex (Inosine Pranobex) is an immunomodulatory agent with broad-spectrum antiviral properties
The move comes a few weeks after receiving the EUA for children between the ages of 5 and 12
The mRNA vaccine candidate is fully indigenous and devoid of any technology contributions from elsewhere
The licences will allow manufacturers from around the world to work with MPP and C-TAP to make these technologies accessible to people living in low- and middle-income countries
Boehringer Ingelheim continues to innovate to enhance the customer experience and improve animal health and well-being
AKS-452 is currently undergoing Phase II/III clinical testing in India as a primary vaccine; submission for Emergency Use Authorization (EUA) expected by Q3 2022
ASC22 (Envafolimab) is a subcutaneously administered single-domain antibody against PD-L1 and has the potential to restore virus-specific immune responses in patients with chronic viral infection
CEPI will provide funding of up to US $19.3 million to support the development of a ‘variant-proof’ SARS-CoV-2 vaccine candidate to an international multidisciplinary consortium
SCG101 is an autologous T-cell receptor (TCR) T-cell therapy for liver cancer
Subscribe To Our Newsletter & Stay Updated
